N/A
N=666
Culturally-Targeted COVID-19 Communication and SARS-CoV-2 Antibody Testing Evaluation and Uptake
SARS-CoV2 Infection
Bottom Line
View on ClinicalTrials.gov: NCT04957082 ↗Enrolled (actual)
666
Serious AEs
0.0%
Results posted
Jun 2024
Primary outcome: Primary: Number (Percentage) of Participants Requested to Participate in Saliva-based SARS-CoV-2 Antibody Testing — 175; 84; 121 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Culturally Targeted SARS-CoV-2 Communication (Behavioral); General SARS-CoV-2 Communication (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Michigan State University
- Primary completion
- Dec 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number (Percentage) of Participants Requested to Participate in Saliva-based SARS-CoV-2 Antibody Testing |
175; 84; 121 | — |
| PRIMARY Number (Percentage) of Participants Who Requested Saliva-based SARS-CoV-2 Antibody Testing Participated in the Testing. |
111; 55; 79 | — |
| PRIMARY SARS-CoV-2 Antibody Testing Attitudes |
5.91; 5.61; 5.71 | — |
| PRIMARY SARS-CoV-2 Antibody Testing Normative Beliefs |
4.71; 4.69; 4.85 | — |
| PRIMARY Antibody Testing Perceived Behavioral Control |
5.88; 5.71; 5.76 | — |
| PRIMARY Antibody Testing Intentions |
4.81; 4.61; 4.83 | — |
| PRIMARY Antibody Testing Anticipatory Racism |
1.79; 2.93; 2.94 | — |
Summary
This disparities-focused study seeks to evaluate communication strategies for better encouraging understanding and uptake of salivary SARS-CoV-2 antibody testing among African Americans residing in Flint, Michigan. This iteration will consider individuals recruited from the Flint Registry and assess willingness to participate in a drive-up saliva sample collection taking place at a central location in Flint, Michigan.
Eligibility Criteria
Inclusion Criteria
- African American or White, 18 or older, and enrolled in the Flint Registry
Exclusion Criteria
- All who do not meet inclusion criteria.
Data sourced from ClinicalTrials.gov (NCT04957082). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.